Acid Sphingomyelinase Deficiency
0
Pipeline Programs
14
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
14 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
SanofirhASM
Hope PharmaceuticalsConfirmatory Testing
Clinical Trials (2)
Total enrollment: 100,011 patients across 2 trials
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
Start: Dec 2006Est. completion: Apr 200911 patients
Phase 1Terminated
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Start: May 2021Est. completion: Aug 2029100,000 patients
N/AEnrolling By Invitation
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
14 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.